What did @hydromedspa actually say?
The creator's core argument is straightforward: if a TRT clinic automatically prescribes estrogen blockers and HCG without lab data, a real conversation, or individualized reasoning, you should leave. Dr. Travis Jeffers from Roger Medspa frames this as a red flag for profit-driven, cookie-cutter prescribing.
He also bundles several agents under the HCG umbrella, including anastrozole-type estrogen blockers, HCG itself, clomiphene citrate (Clomid), gonadorelin, and enclomiphene. His claim is that throwing all of these at a patient from day one, without clinical justification, is a sign the clinic is chasing revenue rather than outcomes. That framing is fair and worth unpacking carefully.
Does the science back this up?
Yes, largely. The evidence base for routine, prophylactic co-prescribing of aromatase inhibitors with TRT is weak. Most clinical guidelines do not recommend starting an aromatase inhibitor unless a patient develops symptomatic hyperestrogenism confirmed by labs.
The Endocrine Society's 2018 clinical practice guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) explicitly state that aromatase inhibitors should not be routinely co-prescribed with testosterone therapy. Prescribing them prophylactically suppresses estradiol below physiological levels, which is linked to reduced bone mineral density, impaired libido, and mood disruption in men. A 2017 study by Finkelstein et al. in the New England Journal of Medicine demonstrated that estrogens play a significant independent role in male sexual function, which makes blanket suppression genuinely harmful. HCG and gonadotropin-stimulating agents like clomiphene are similarly context-dependent. There is legitimate evidence for their use in fertility preservation or hypogonadotropic hypogonadism, but routine co-prescribing for every TRT patient is not evidence-based practice.
What did they get wrong or right?
The creator gets the main point right. Automatic, protocol-driven co-prescribing without labs or informed consent is a real problem in the direct-to-consumer TRT space. Give credit where it is due.
Where the video is imprecise: gonadorelin and HCG are not equivalent agents. HCG is an LH analog that directly stimulates testicular Leydig cells. Gonadorelin is a GnRH analog that works upstream at the pituitary. Clomiphene is a selective estrogen receptor modulator, not an LH or GnRH agent at all. Lumping them together as interchangeable is clinically sloppy, even if the broader point about individualization holds. The creator also does not distinguish between situations where these agents are actually appropriate, for example, a patient who wants to preserve fertility or who presents with secondary hypogonadism, versus situations where they are unnecessary add-ons. A blanket warning to run from any clinic that mentions HCG or estrogen blockers could steer patients away from clinicians who are prescribing them correctly and for documented clinical reasons. The nuance matters.
What should you actually know?
If a TRT clinic hands you a prescription for anastrozole, HCG, and testosterone on your first visit without reviewing your labs or explaining why each drug is included, that is a problem. But the solution is not to fear these medications. It is to demand an explanation grounded in your specific bloodwork and symptoms.
Aromatase inhibitors have a real clinical role in TRT management when estradiol is objectively elevated and causing symptoms. HCG has documented value for testicular atrophy prevention and fertility preservation in men who care about those outcomes. Clomiphene and gonadorelin are useful in specific clinical scenarios, particularly hypogonadotropic hypogonadism. The red flag the creator is identifying is not the medications themselves. It is the absence of individualized clinical reasoning. Ask your provider why each medication is on your prescription. If they cannot answer that question with reference to your labs and your goals, find a different provider.
- Bhasin et al. (2018, JCEM) recommend against routine aromatase inhibitor use with TRT.
- Finkelstein et al. (2013, NEJM) showed estrogens are essential for male libido and bone health.
- HCG co-therapy has evidence for preserving testicular volume and spermatogenesis (Hsieh et al., 2013, Journal of Urology), but is not required for every patient.